EARCO is a clinical research collaboration of the European Respiratory Society (ERS). It is an international scientific network committed to promotion, research and education in alpha-1 antitrypsin deficiency (AATD). Its main objective is to create an international database that includes demographic and clinical data of patients with AATD to provide longitudinal real-world data on individuals with this disease.

The Earco Registry

The aim of the registry is to collect prospective, non-interventional, multi-centre, standardized, longitudinal data on an international level necessary to evaluate:

  • The natural history of the disease
  • The influence of risk factors
  • Other genetic determinants
  • The role of augmentation therapy in the prognosis of the disease elements

The major inclusion criterion is: severe AATD, defined by an AAT serum level < 11 μM (50 mg/dl) and/or a proteinase inhibitor; genotype ZZ, SZ, and compound heterozygotes or homozygotes of other rare deficient variants (non-M).

Secure Login New Account? Apply here.